Cytology Assessment Can Predict Survival for Patients With Metastatic Pancreatic Neuroendocrine Neoplasms

被引:11
|
作者
Sigel, Carlie S. [1 ]
Guo, Huimin [1 ]
Sigel, Keith M. [2 ]
Zhang, Ming [1 ]
Rekhtman, Natasha [1 ]
Lin, Oscar [1 ]
Klimstra, David S. [1 ]
Jungbluth, Achim A. [1 ]
Tang, Laura K. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA
[2] Icahn Sch Med Mt Sinai, Div Gen Internal Med, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
cytology; grade; differentiation; Ki-67; index; metastatic; neuroendocrine carcinoma; pancreas; pancreatic neuroendocrine tumor; HIGH-GRADE; LABELING INDEX; TUMORS; CARCINOMAS; DISTINCT; CELL;
D O I
10.1002/cncy.21817
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Histological features and Ki-67 index have known usefulness in predicting prognosis and guiding therapy among patients with metastatic pancreatic neuroendocrine neoplasms. Fine-needle aspiration may offer advantages for Ki-67 assessment because the technique obtains highly cellular, well-preserved specimens with the potential for broader tumor sampling. In the current study, the authors evaluated concordance for grade and differentiation between concurrent core needle biopsy and cytology preparations. Cytological features and grade then were correlated with survival. METHODS: Differentiation, grade by Ki-67 index, and correlation of these features with survival were compared between concurrent core needle biopsy and cytology specimens from 44 patients with metastatic pancreatic neuroendocrine neoplasms. RESULTS: Differentiation by cytology smear resulted in 38 cases of well (86%) and 6 cases of poor (14%) differentiation. Agreement for differentiation between smear and cell block, smear and core needle biopsy, and cell block and core needle biopsy was 88%, 94%, and 83%, respectively, and agreement for grade was 68%, 54%, and 22%, respectively. Cytology differentiation and cytology grade were found to be strong predictors of outcome with respective hazard ratios of 8.3 (95% confidence interval [95% CI], 3.1-22.1; P<.001) and 1.9 (95% CI, 1.2-2.9) for each ascending grade. The median disease-specific survival cytology projections were 121 months (95% CI, 57-185 months [estimated]) for grade 1, 45 months (95% CI, 29-87 months) for grade 2, and 19 months (95% CI, 1-44 months) for grade 3, with median survivals of 45 months and 3 months, respectively, for patients with well-differentiated and poorly differentiated neuroendocrine tumors (P<. 001). CONCLUSIONS: Grading of pancreatic neuroendocrine neoplasms on cytology may not correlate exactly with concurrent core needle biopsy, but cytology differentiation and grade are predictive of survival based on stage-adjusted analysis. (C) 2017 American Cancer Society.
引用
收藏
页码:188 / 196
页数:9
相关论文
共 50 条
  • [31] A Cure Model Survival Analysis of Patients Affected by Pancreatic Neuroendocrine Neoplasms: The Bologna ENETS Center Experience
    Ricci, C.
    Campana, D.
    Ingaldi, C.
    Alberici, L.
    Mosconi, C.
    Ambrosini, V
    Brighi, N.
    Santini, D.
    Pagano, N.
    Casadei, R.
    NEUROENDOCRINOLOGY, 2019, 108 : 259 - 259
  • [32] Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors
    Meng-Xia Li
    Qi-Yong Li
    Min Xiao
    Da-Long Wan
    Xin-Hua Chen
    Lin Zhou
    Hai-Yang Xie
    Shu-Sen Zheng
    Hepatobiliary & Pancreatic Diseases International, 2019, 18 (06) : 538 - 545
  • [33] Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors
    Li, Meng-Xia
    Li, Qi-Yong
    Xiao, Min
    Wan, Da-Long
    Chen, Xin-Hua
    Zhou, Lin
    Xie, Hai-Yang
    Zheng, Shu-Sen
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2019, 18 (06) : 538 - 545
  • [34] Pancreatic steatosis and its correlation with clinicopathological features in patients with pancreatic neuroendocrine neoplasms
    Li Yongzheng
    Yang Jian
    Fan Zhiyao
    Dong Peng
    Hu Jingjuan
    Liu Shujie
    Meng Yufan
    Gao Changhao
    Gao Xin
    Pang Chaoyu
    Zhan Hanxiang
    胰腺病学杂志(英文), 2023, 06 (02)
  • [35] Pancreatic steatosis and its correlation with clinicopathological feature in patients with pancreatic neuroendocrine neoplasms
    Li, Y.
    Yang, J.
    Fan, Z. Y.
    Liu, S. J.
    Meng, Y. F.
    Gao, C. H.
    Gao, X.
    Pang, C. Y.
    Zhan, H. X.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 92 - 92
  • [36] Pancreatic steatosis and its correlation with clinicopathological features in patients with pancreatic neuroendocrine neoplasms
    Li, Yongzheng
    Yang, Jian
    Fan, Zhiyao
    Dong, Peng
    Hu, Jingjuan
    Liu, Shujie
    Meng, Yufan
    Gao, Changhao
    Gao, Xin
    Pang, Chaoyu
    Zhan, Hanxiang
    JOURNAL OF PANCREATOLOGY, 2023, 6 (02) : 48 - 54
  • [37] Can clinical and histological parameter predict prognosis in patients with metastatic neuroendocrine gastroentetropancreatic (GEP) tumors?
    Wied, M
    Sprenger, A
    Barth, PS
    Mueller, HH
    Arnold, R
    GASTROENTEROLOGY, 2000, 118 (04) : A514 - A515
  • [38] Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms
    Werner, Wiebke
    Detjen, Katharina
    Bruneau, Alix
    Lurje, Isabella
    Nestel, Natalie
    Jann, Henning
    Tacke, Frank
    Wiedenmann, Bertram
    Roderburg, Christoph
    Hammerich, Linda
    ENDOCRINE-RELATED CANCER, 2023, 30 (07)
  • [39] Nomogram for predicting survival of patients with metastatic nonfunctioning pancreatic neuroendocrine tumors A SEER based study
    Ge, Lina
    Li, Haijin
    Dong, Liang
    Shang, Guanmin
    Wang, Weiying
    Li, Ying
    Qi, Liping
    Zhao, Jiangang
    Peng, Dengfu
    Tong, Guoqi
    MEDICINE, 2021, 100 (27)
  • [40] Determinants of Survival in Patients with Pancreatic Neuroendocrine Tumors
    Keck, K.
    Breheny, P.
    Choi, A.
    Maxwell, J. E.
    Dillon, J. S.
    Chan, C. H.
    Hoshi, H.
    Bellizzi, A.
    O'Dorisio, T.
    Howe, J. R.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S94 - S95